Key result
Human induced pluripotent stem cells and gene-editing techniques provide valuable in vitro patient-specific models to elucidate the pathophysiology and test therapies for genetic cardiomyopathies.
Why the study?
Assessing the pathogenicity of newly discovered genetic variants in genetic cardiomyopathies requires in-depth characterization to ascertain their causal role in disease.
hiPSC-derived models and gene-editing technologies are essential tools for elucidating the pathophysiology of genetic cardiomyopathies and developing novel targeted therapies.
hiPSC models extend genetic cardiomyopathy research; clinical translation remains open pending validation.
Genetic cardiomyopathies represent a wide spectrum of inherited diseases and constitute an important cause of morbidity and mortality among young people, which can manifest with heart failure, arrhythmias, and/or sudden cardiac death. Multiple underlying genetic variants and molecular pathways have been discovered in recent years; however, assessing the pathogenicity of new variants often needs in-depth characterization in order to ascertain a causal role in the disease. The application of human induced pluripotent stem cells has greatly helped to advance our knowledge in this field and enabled to obtain numerous in vitro patient-specific cellular models useful to study the underlying molecular mechanisms and test new therapeutic strategies. A milestone in the research of genetically determined heart disease was the introduction of genomic technologies that provided unparalleled opportunities to explore the genetic architecture of cardiomyopathies, thanks to the generation of isogenic pairs. The aim of this review is to provide an overview of the main research that helped elucidate the pathophysiology of the most common genetic cardiomyopathies: hypertrophic, dilated, arrhythmogenic, and left ventricular noncompaction cardiomyopathies. A special focus is provided on the application of gene-editing techniques in understanding key disease characteristics and on the therapeutic approaches that have been tested.
No takes yet. Share an insight, caveat, or question.
My et al. (2021) conducted a review in Genetic cardiomyopathies. Human induced pluripotent stem cells (hiPSCs) was evaluated. Human induced pluripotent stem cells and gene-editing techniques provide valuable in vitro patient-specific models to elucidate the pathophysiology and test therapies for genetic cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: